既往生物制剂治疗及IFN-γ/IL-10轴受损与脊柱关节炎患者对17DD-YF疫苗接种的低免疫应答相关
这项前瞻性研究纳入51例脊柱关节炎患者和23名健康对照,评估17DD-YF疫苗接种后的免疫应答。脊柱关节炎组中和抗体滴度和血清阳性率均低于健康对照组;既往使用生物制剂者抗体应答更低,而疾病活动度(BASDAI)与抗体水平无关。
要点
- 脊柱关节炎患者接种17DD-YF后中和抗体几何均值112 vs 健康对照440,血清阳性率73% vs 96%。
- 既往生物制剂组中和抗体几何均值79(95%CI 39-150)vs 未用生物制剂组159(95%CI 94-267),p<0.001。
- 未用生物制剂组血清阳转率81% vs 健康对照96%(p=0.112),生物制剂组64% vs 健康对照96%(p=0.007)。
核心结论
- 研究提示生物制剂的使用影响脊柱关节炎患者对17DD-YF疫苗的应答,即使经过计划洗脱。
- 既往生物制剂治疗、接种前炎症状态及病毒血症峰值时IFN-γ/IL-10轴受损可能决定17DD-YF疫苗的免疫原性。
研究设计与样本
- 前瞻性研究纳入74名受试者,包括成人脊柱关节炎患者51例和健康对照23名。
- 在D0、D3、D4、D5、D6、D7、D14和D28多个时间点检测黄热病特异性中和抗体试验(PRNT)、黄热病病毒血症及血清趋化因子、细胞因子和生长因子水平。
- BASDAI评分在D0和D180评估。
主要发现
- 脊柱关节炎组PRNT滴度和血清阳性率低于健康对照组(几何均值112 vs 440;73% vs 96%)。
- 既往生物制剂组PRNT滴度低于未用生物制剂组(79,95%CI 39-150 vs 159,95%CI 94-267,p<0.001)。
- 未用生物制剂组血清阳转率与健康对照组相似(81% vs 96%,p=0.112),生物制剂组血清阳转率低于健康对照组(64% vs 96%,p=0.007)。
- BASDAI与PRNT水平无关,随访6个月后BASDAI无变化;各组间黄热病病毒血症无差异。
- 生物制剂组基线血清生物标志物水平高于未用生物制剂组,BASDAI≥4者高于BASDAI<4者;脊柱关节炎患者中多个生物标志物水平随时间升高,尤其在生物制剂组和BASDAI≥4亚组,病毒血症峰值(D5)前后IFN-γ/IL-10轴受损/紊乱。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Yellow fever (YF) vaccination is known to induce a suboptimal response in patients with autoimmune diseases (AIDs). To date, few studies have focused on the performance of 17DD-YF vaccination in patients with spondyloarthritis (SpA). In general, patients with SpA are young and have less comorbidities than other patients with AIDs, and frequently receive biological disease-modifying antirheumatic drugs (DMARDs) that may impact their response to vaccines. Taking this background information, the present study aimed to investigate whether the use of biological DMARDs, even after planned washout, or disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), would impact the overall performance of planned 17DD-YF primary vaccination in patients with SpA. For this purpose, 74 subjects were enrolled in a prospective study, including adult patients with SpA (SpA; n = 51) and a healthy control (HC; n = 23) group. Analysis of YF specific neutralizing antibodies test (PRNT), along with YF viremia and the levels of serum chemokines, cytokines, and growth factors were performed at distinct time points (D0, D3, D4, D5, D6, D7, D14, and D28). The BASDAI scores were evaluated at D0 and D180. Data demonstrated that overall, the SpA group presented lower PRNT titers and seropositivity rates as compared to the HC group (GeoMean = 112 vs. 440; 73% vs. 96%, respectively). In SpA subgroup analyses, previous biological DMARDs (BIO-IT) led to a lower PRNT titers (BIO-IT 79, 95% CI [39-150] vs. without biological DMARDs [non-BIO-IT] 159, 95% CI [94-267], p < 0.001). The non-BIO-IT group achieved a response similar to the HC group (81% vs. 96%, p = 0.112), whereas the BIO-IT group had a lower seroconversion rate (64% vs. 96% HC, p = 0.007). The BASDAI was not associated with PRNT levels and did not change after 6 months of follow-up. No differences in YF viremia were observed amongst subgroups. Higher baseline levels of serum biomarkers were observed in the BIO-IT group vs. the non-BIO-IT group, as well as in those with a BASDAI ≥ 4 vs. those with a BASDAI < 4. Increasing levels of several biomarkers were observed in SpA, especially in the BIO-IT and BASDAI ≥ 4 subgroups throughout the timeline kinetics, with impairment/disturbance in the IFN-γ/IL-10 axis around the peak of viremia (D5). Altogether, these findings suggested that the use of biological DMARDs impacts the response to the 17DD-YF vaccine, even after planned washout. Therefore, previous biological DMARD therapy, the inflammatory status prior vaccination, and impairment of the IFN-γ/IL-10 axis at the peak of viremia may determine the immunogenicity of 17DD-YF vaccination in patients with SpA.
引用
- Casagrande TZ, Costa-Rocha IAD, Gavi MBRO, et al. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis. Vaccine. 2022. PMID: 35728990. doi:10.1016/j.vaccine.2022.05.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。